Contagious caprine pleuropneumonia (CCPP) is a severe disease of goats occurring in many countries in Africa and Asia. It has been causing loss to Ethiopian goats contributing to the expansion of poverty of goat rearing society. In Ethiopia the inactivated CCPP vaccine has been produced and used. However, the vaccine produced by the institute could not satisfy the domestic demand let alone the foreign country demand. The nature of the seed strain, and the length of CCPP vaccine production process involving centrifugation and concentration which has time cost and involve expensive equipments has constrained the vaccine demand in NVI. As the result, the production technique which bypasses such lengthy production process and increase the vaccine yield per annual is mandatory. This study aimed to evaluate the safety and immunogenicity of whole culture CCPP trial vaccine which was produced by bypassing the lengthy centrifugation or concentration process. After the vaccine was produced its safety was confirmed and Mccp antibody free goats were grouped in to three and vaccinated and antibody level were evaluated by c-ELISA for eight weeks duration. The data obtained from safety and immunogenicity test results were analyzed by independent sample t-test and ANOVA by considering confidence interval of 95% and desired level of significance of 0.05. During comparison of safety tested and percent positive results, significance difference was not observed (p>0.05) but Comparison of the mean percent inhibition between whole culture vaccinated (61.52Â±2.92), positive control vaccinated (51.86Â±4.95) and negative control (40.65Â±2.84) showed presence of significant difference p